Search Results

BOTHELL, Wash.--(BUSINESS WIRE)-- Iverson Genetic Diagnostics, Inc. announced today a partnership agreement with Vanderbilt University under which Iverson receives global exclusive commercialization rights for molecular diagnostics that will help physicians to assess breast cancer risk in women considering hormone replacement therapy during menopause. Research suggests that estrogen metabolites represent one of several determinants of the risk of breast cancer